Have your say! Access to new medicines and novel technologies in ovarian cancer.

 Ovarian Cancer Australia welcomes the Parliamentary Inquiry into new drugs and novel technologies. The Inquiry by the House of Representatives Standing Committee on Health, Aged Care and Sport will include a focus on access to treatment for rare diseases and conditions where there is high and unmet need.

The ovarian cancer community has a wealth of knowledge and real-life experiences that should be shared. Please consider having your say to ensure that the Inquiry’s outcomes are focused on the needs of women with ovarian cancer.

 There are two ways that you can have your say:

1.     Complete the survey below and your responses will be included in the Ovarian Cancer Australia Submission. Please complete this by 7 October 2020.

2.     You can complete your own submission all information on how you can do this is at the following link Senate inquiry website the closing date is 13 October 2020.

Thank-you to everyone who decides to support Ovarian Cancer Australia’s efforts for improving access to new drugs and technology.  It will help eliminate the obstacles and pave the way for faster access to medicines and novel technologies  in the future for people with ovarian cancer. 

Question Title

* 1. What does it mean to you to have  more drugs available to treat your ovarian cancer?

Question Title

* 2. Has your treatment team prescribed a medication for you that was not available of the Pharmaceautical Benefits Scheme (PBS)?

Question Title

* 3. What were the main challenges for you  with the medicine not being available on the PBS?

Question Title

* 4. What does it mean to you to have access to international ovarian cancer drug trials within Australia?

Question Title

* 5. What does it mean to you to have new  ovarian cancer drugs listed quickly on the Pharmaceutical Benefits Scheme (PBS)?

Question Title

* 6. Do you have any other comments on access to medicines and novel technologies for women with ovarian cancer in Australia?

0 of 6 answered
 

T